The size of the Perfusion Systems Market in North America is predicted at USD 0.42 billion in 2023. This value is forecasted to be at a CAGR of 4.5% and worth USD 0.52 billion by 2028.
The increase in the number of transplantation surgeries happening in the North American countries is significantly boosting the perfusion systems market in this region. As per the statistics published by the U.S. Department of Health and Human Services, over 119,000 people are in the queue for transplantations, and only 2,555 donors are obtainable as of April 2017. They are predicted to rise more in the forthcoming years. Growing gaps between the demand and supply, the rise in the number of approvals, and the introduction of novel perfusion systems are further encouraging the growth rate of the market in the forthcoming years. For instance, nearly 100,791 people in the United States have geared up for kidney transplants, as per the report announced by the National Kidney Foundation as of 2016. More than 117,000 males, females, and children were on the national transplant standby till July 2017, and 17,155 organ transplants were implemented in the U.S., according to the Organ Procurement and Transplant Network (OPTN).
Pressure for efficient perfusion systems is accelerating by the growing number of organ failures because of alcohol consumption, improper diet, and smoking is accelerating the need for these systems in North America. According to the approximations created by the National Institute of Diabetes and Digestive and Kidney Diseases, 661,000 people were registered for kidney failure in the U.S. For instance, METRA developed by OrganOx Ltd. used for automatic liver transplantation and normothermic liver perfusion is still under clinical trials in the United States. Technically invented products for the sake of developed efficacy and economy are expected to produce profitable opportunities in the region.
The high costs associated with organ transplantation is a prime factor hindering the market growth. Also, behavioral issues and tough competition from the domestic key players with less-cost products hamper the perfusion systems market growth in North America. People with less or no knowledge about the perfusion systems market are another factor impeding the region's growth.
This research report on the North America Perfusion Systems Market has been segmented and sub-segmented into the following categories:
Based on the region, North America has the highest no. share in this market. The USA has the highest demand, followed by Canada and Mexico. The North American region is primarily driven by environmental concerns.
U.S and Canada are the foremost leading nations in the region, contributing the majority of the total market share. Amplifying the number of chronic diseases regarding lungs, heart, liver, and kidneys escalate the region's market. The fructifying number of heart and kidney bypass surgeries and people having more knowledge about the surgeries to be performed using advanced technologies are prompting the perfusion systems market's growth rate in North America.
The burgeoning pervasiveness of coronary diseases adjacent to the quick approval of modern technologies and devices utilized in the surgical procedures flourish the market growth. The United States is leading the perfusion systems market, as most key players are engaged in elaborating novel products utilized in clinical trials.
The U.S. government has taken some initiatives from nonprofit organizations like Donate Life America to bring awareness to people, which escalates market growth.
Promising Companies leading the North America Perfusion Systems Market Profiled in the Report are Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, XENIOS AG, Repligen Corporation, Spectrum Laboratories, Inc, Merck KGaA, Harvard Bioscience, Inc, ALA Scientific Instruments, Inc.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org